Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil
Rev. Soc. Bras. Med. Trop
;
53: e20190594, 2020. tab, graf
Artículo
en Inglés
| SES-SP, ColecionaSUS, LILACS
| ID: biblio-1136866
ABSTRACT
Abstract INTRODUCTION We conducted a cost-utility analysis of available interferon-free treatments for patients with early-stage genotype 1 chronic hepatitis C based on a Brazilian public health system perspective. METHODS A Markov model was derived using a cohort of stage F0-F2 patients treated as recommended by the Brazilian national guidelines. RESULTS:
Glecaprevir plus pibrentasvir was superior to all other treatments, followed by sofosbuvir plus velpatasvir. Sofosbuvir plus daclatasvir was identified as the least cost-effective option.CONCLUSIONS:
The above findings were confirmed via probabilistic sensitivity analysis and the tested scenarios.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Antivirales
/
Hepacivirus
/
Hepatitis C Crónica
/
Quimioterapia Combinada
Tipo de estudio:
Guía de Práctica Clínica
/
Evaluación Económica en Salud
/
Estudio pronóstico
Límite:
Humanos
País/Región como asunto:
America del Sur
/
Brasil
Idioma:
Inglés
Revista:
Rev. Soc. Bras. Med. Trop
Año:
2020
Tipo del documento:
Artículo
Institución/País de afiliación:
Universidade Federal do Paraná/BR
Similares
MEDLINE
...
LILACS
LIS